ODDB.org: Open Drug Database | Medikamente

Home - FI zu Ezetimib-Rosuvastatin Viatris

Fachinformation zu Ezetimib-Rosuvastatin Viatris:

Viatris Pharma GmbH

C10BA06 - Rosuvastatin and Ezetimibe

ATC-DDD Version 2016. Source: WHO

C - Cardiovascular System

This group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, and C03.

C10 - Lipid Modifying Agents

The DDDs are based on the treatment of hypercholesterolemia.

C10B - Lipid Modifying Agents, Combinations

Fixed combinations of blood glucose-lowering drugs and lipid modifying agents are classified in A10B.

For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.

C10BA - Combinations Of Various Lipid Modifying Agents

The DDD for the fixed combination of simvastatin or atorvastatin and ezetimibe is 1 UD (1 tablet), regardless of strength.
The DDD for the fixed combination of pravastatin and fenofibrate is 1 UD (1 tablet), regardless of strength.

C10BA06 - Rosuvastatin and Ezetimibe

2024	©ywesee GmbH